Introduction
============

Over the last decades, the occurrence of obesity and chronic diseases has increased dramatically among adults worldwide.^[@r1]^ On the other hand, advances in medical sciences, development of new generation of medicines/therapies, have significantly improved quality of life and longevity.^[@r2],[@r3]^

In developing countries, the use of any medicine is reported by 60% of the adult population, while the use of three or more medicines in the last two weeks is reported by about 18% of the population.^[@r4]^ A similar pattern is observed in Central Eastern Europe where more than 20% of adults (18 years plus) report three or more medicine use.^[@r5]^ Narayan et al.^[@r3]^ found that in a period of nine years (from 2005 to 2013) the use of drugs for prevention purposes (aspirin, clopidogrel, statins and bisphosphonates) increased significantly among New Zealand adults aged 65 years or more (about 19.5%, 2.9%, 7% and 2.3%, respectively).

The dramatic rise in the prevalence of obesity and its associations with the development of metabolic and cardiovascular diseases would explain, at least in part, this increase trend.^[@r1],[@r6]^ In fact, wide access to medicines by population signifies an improvement in the prevention/treatment of diseases.^[@r2]^ However, the potential adverse drug reactions generated by the use of unprescribed medicines constitute a global public health concern related to high healthcare costs.^[@r7],[@r8]^

The economic burden related to medicine use involves not only health care costs resulting from inappropriate medication but also the purchase of prescribed and unprescribed medicines (public and out of pocket expenses).^[@r7],[@r9]^ For example, in a period of five years from 2000 to 2004, the Brazilian Ministry of Health expended US\$ 916 million in programs to provide high-cost drugs to population.^[@r10]^ Despite the increasing economic burden related to medicines use, little is known about its underlying determinants. We need to know these determinants in order to identify target areas for policy making on managing health budgets, particularly in health systems in developing settings.

Unhealthy lifestyle behaviors (alcohol consumption, smoking, poor sleep habits and sedentary behaviors \[SB\]) have been shown to play an important role in the development of many diseases,^[@r11]^ but their direct relationship with the costs related to medicines use is unclear. For example, the occurrence of sleep disorders is highly prevalent in adults,^[@r12]^ but its economic burden is unknown.^[@r13]^ A longitudinal study carried out with 11,698 American employees identified that how worse were the sleep disorder reported the health care costs to increase in average US\$ 725.15.^[@r13]^ Similarly, in a 12-months study carried out in Taiwan, adults with positive diagnosis to obstructive sleep apnea were 66% more expensive (in terms of physician diagnoses, medications, treatments, surgeries, laboratory tests and diagnostic imaging) than those adults without the same diagnosis (US\$ 1,734.10 versus US\$ 1,041.30, respectively).^[@r14]^ Conversely, improved levels of physical activity (PA) could reduce costs related to medicine use in adults,^[@r15],[@r16]^ but its role in the potential relationship between unhealthy lifestyle behaviors and costs of medicine use has not been studied to date.

In this study, we examine the interrelationship between costs of medicine use and lifestyle behaviors (both healthy and unhealthy).

Methods
=======

Sample
------

The data comes from a cohort study carried out in the city of Presidente Prudente which presents human development index 0.806,^[@r17]^ placed on western Sao Paulo State (which is the state of the most industrialized Brazilian federation) from February/June 2014 (baseline) to May/December 2015 (follow-up). Sample size estimation was based on an equation for the correlation coefficient. Due to the absence of specific data about the relationship between lifestyle behaviors and health care costs in Brazil,^[@r16],[@r18]^ we have adopted a correlation coefficient of 0.30 between PA and health care costs,^[@r16],[@r18]^ z = 1.96 and power of 80% (adopting the above-mentioned parameters, the minimum sample size required for this study was 86 participants). The inclusion criteria for participants were: 40-65 years old, no diagnosis of previous cardiovascular complications (e.g. stroke, heart attack), no diabetes complications (amputation or visual problems), no regular medication use, and no physical disability.

Invitation to participate in the study was conducted using advertisements (ie posters) in the Sao Paulo State University in Presidente Prudente and gyms/fitness centers across the city. Interested participants contacted the research staff, who then checked the profile of the participants against the inclusion criteria (participants who met all the inclusion criteria signed a written consent form). One hundred ninety-eight adults contacted the research staff and were considered eligible and undertook baseline assessment. The analysis herein covered 118 subjects (44 men and 74 women) assessed at both baseline and follow-up (12 months later). The excluded people were due to (a) dropouts (n = 62) and (b) provision of less than seven days of pedometer use at baseline (n = 18).

All procedures (questionnaires, pedometers and body composition assessment) were performed by trained staff of researchers (Professors, MSc and PhD students) following the protocols of the Laboratory of Investigation in Exercise (LIVE), Brazil.^[@r19]^ The Ethics committee of the Sao Paulo State University (UNESP), campus of Presidente Prudente, approved the study.

Costs of medicines use
----------------------

At baseline, the participants were given a questionnaire (in diary form) for medicine use and instructions (further clarification offered face to face by research staff) on how to fulfil the questionnaire. The participants reported the following data: (a) number and type of all medicines (prescribed and unprescribed); (b) how they obtained the medicines - through the Brazilian National Health System \[BNHS\] or out of pocket expenditure. The diary was filled for each of the 12 months of the cohort study. At the end of the follow-up period, the research staff collected back the completed diaries ([Table 1](#t1){ref-type="table"}). To calculate the cost of medicines, we used national prices presented by BNHS (for medicines delivered by the BNHS) and market prices from drug stores in the study area (medicines obtained via personal expenses). Costs were computed in Brazilian currency (Real\$) and converted to US dollar (US\$) using the cambial information provided by the Central Bank of Brazil.

###### 

Most frequently bought medicines according to anatomical therapeutic chemical code

  Anatomical Therapeutic Chemical Code     Types of medicine   Number of medicines bought
  ---------------------------------------- ------------------- ----------------------------
  Digestive tract and metabolism           18                  33
  Blood and Blood-forming organs           2                   2
  Cardiovascular system                    31                  42
  Dermatological                           1                   1
  Genito-urinary system and sex hormones   9                   25
  Hormones, except sexual and insulin      10                  10
  Systemic anti-infective agents           1                   1
  Anti-neoplastics and immune modulators   1                   2
  Muscle-skeletal system                   7                   9
  Nervous system                           28                  38
  Antiparasitics                           1                   2
  Respiratory system                       3                   3
  Sensory organs                           1                   1
  Other                                    1                   3
  Overall                                  114                 172

Lifestyle behavioral variables
------------------------------

PA was measured using both objective and subjective measures at baseline and follow-up. Objective measure of PA was collected using pedometers (Yamax digiwalker, SW200 model, Japan), and specified in terms of step count. At both assessments periods (baseline and follow-up), pedometers were worn by participants for seven consecutive days. The pedometers were fixed laterally at the hip and were taken off only during periods of sleep and water-based activities. Participants logged (at the end of each day) the total step count. In the present study, PA denoted the number of days (out of 14 days assessed) that ≥7,500 steps were achieved. In line with Tudor-Locke et al.,^[@r20]^ participants who reached ≥7,500 steps/day were classified as "sufficiently active". The subjective measure of PA was collected using Baecke's questionnaire.^[@r21]^ The questionnaire is composed of 16 questions about three PA domains (occupational, sports participation and leisure-time PA).

Data on SB at work (both baseline and follow up) were captured using the following question: "At work I sit"...; potential responses were: never \[score attributed = 1\], seldom \[score attributed = 2\], sometimes \[score attributed = 3\], often \[score attributed = 4\] and very often \[score attributed = 5\]).

Quality of sleep was assessed at baseline and follow up using the Mini-Sleep Questionnaire,^[@r22]^ which includes 10 questions, each one with seven possible answers (ranging from never to always). The sum of these 10 answers generates a numerical score ranging from 10 to 70 points (higher scores indicate worse sleep quality).

Participants also self-reported at baseline and follow-up smoking status (yes or no current smoker) and weekly alcohol consumption (number of days per week with alcohol consumption).

Covariates
----------

Covariates were data collected via questionnaire (sex \[male or female\], date of birth \[chronological age estimated using the difference between birthday and date of assessment\] and formal schooling \[in years\]). Clinical data also were evaluated (body fatness \[dual-energy X-ray absorptiometry\], systolic and diastolic blood pressure respectively). Researchers performed the clinical measures in university facilities with controlled temperature and followed standardized procedures.

Statistical analyses
--------------------

Descriptive statistics were undertaken using mean, 95% confidence intervals (95%CI) and proportions as appropriate. Due to non-parametric distribution (attested by Kolmogorov-Smirnov test), the costs of medicine use were converted into base-10 logarithms.

Both the Pearson correlation and linear regression were conducted to assess the relationship between the costs of medicines and the independent variables. In the former approach, Pearson correlation (expressed as standardized coefficients \["*r*" values\]) analyzed the relationship of the costs of medicine use with lifestyle behaviors (sleep quality, PA, SB at work, smoking and alcohol consumption) and covariates (sex, age, schooling, blood pressure and body fatness) separately. In the latter, linear regression models (expressed as unstandardized coefficients \[β values\]) were fitted to examine the relationship between the costs of medicine use and lifestyle behaviors controlling for all covariates. For each approach, four models were fitted based on different specifications of lifestyle behaviors (\[A\] only baseline values, \[B\] only follow-up values, \[C\] difference between follow-up and baseline and \[D\] sum of baseline and follow-up), to explore the differential relationship these specifications may present. Diagnosis of multicollinearity and homoscedasticity were assessed and the linear regression models were considered adequately fit.

All analyzes were performed using BioEstat (version 5.2) and the significance level was set at p-value \< 0.05.

Results
=======

At baseline, the mean age of the sample was 51.7 ± 7.1 years, ranging from 40 to 68 years ([Table 2](#t2){ref-type="table"}). Alcohol was consumed on average 2.1 days per week, while 5.1% of the sample were smokers. Expenses on medicine use were reported by 52.5% of the sample. During 12-months of follow-up, 62 subjects bought 172 medicines ([Table 2](#t2){ref-type="table"}), representing an overall cost of US\$ 3,087.01 for the entire sample. There was no missing data.

###### 

Summarized characteristics of the sample (n = 118)

  Variables                               Descriptive Statistic   
  --------------------------------------- ----------------------- --------------
  Age (years)~baseline~                   51.7 (50.4 to 53.1)     51.1 (10.1)
  Body weight (kg)~baseline~              74.6 (71.7 to 77.4)     72.6 (16.6)
  Height (m)~baseline~                    1.65 (1.63 to 1.67)     1.65 (0.15)
  BMI (Kg/m^2^)~baseline~                 26.92 (26.3 to 27.5)    26.41 (5.98)
  Costs with medicine (US\$)~follow-up~   26.16 (17.7 to 34.62)   1.19 (42.91)
  Alcohol consumption (days)~baseline~    2.1 (1.9 to 2.3)        2 (2)
  Alcohol consumption (days)~follow-up~   1.9 (1.7 to 2.2)        1 (2)
  Sleep quality (MSQ score)~baseline~     26.6 (24.7 to 28.4)     25 (13)
  Sleep quality (MSQ score)~follow-up~    26.8 (24.8 to 28.7)     26 (15)
  PA (≥7,500 steps/day)~baseline~         2.3 (1.8 to 2.7)        1 (5)
  PA (≥7,500 steps/day)~follow-up~        1.9 (1.5 to 2.3)        1 (4)
  SB at work (score)~baseline~            3.2 (2.9 to 3.4)        3 (2)
  SB at work (score)~follow-up~           3.1 (2.9 to 3.3)        3 (2)
  Smoking (yes \[%\])~baseline~           5.1% (1.1% to 9.1%)     \-\--
  Smoking (yes \[%\])~follow-up~          5.9% (1.6% to 10.1%)    \-\--
  Medicine use (yes \[%\]) ~follow-up~    52.5 (43.5% to 61.5%)   \-\--

95% CI: 95% confidence interval; IR: interquartile range; BMI: body mass index; MSQ: mini-sleep questionnaire; PA: physical activity; SB: sedentary behavior.

PA decreased significantly from baseline to follow-up (p-value = 0.024), while the score for SB at work (p-value = 0.396), sleep quality (p-value = 0.951) and alcohol consumption (p-value = 0.100) remained stable between baseline and follow-up.

In the bivariate analysis, costs of medicine use were negatively related to PA ~baseline~ (r = -0.194; p-value = 0.035), PA ~follow-up~ (r = -0.281; p-value = 0.002), but positively related with sleep quality ~baseline~ (r = 0.299; p-value= 0.001) and sleep quality ~follow-up~ (r = 0.315; p-value = 0.001), and age ~baseline~ (r = 0.274; p-value = 0.003). Gender, education, SB at work, alcohol consumption and smoking were not significantly related with costs of medicine use. There was no interrelationships among the lifestyle behaviors.

In the multivariate model considering lifestyle behaviors at baseline (Model-A), sleep quality and body fatness were positively related to higher 12-months medicine costs, while alcohol consumption was negatively related to it. Model-A explained 19.1% of all variance in the outcome ([Table 3](#t3){ref-type="table"}). In the multivariate model considering lifestyle behaviors at follow-up (Model-B), only sleep quality was positively related to higher 12-months medical costs. Model-B explained 21.9% of all variance in the medicine costs.

###### 

Linear regression describing the relationship between 12-months medicine costs (dependent variable) and lifestyle behaviors (n= 118)

  Independent variables                               Model - A                   Model - B                  Model - C                  Model - D
  --------------------------------------------------- --------------------------- -------------------------- -------------------------- ---------------------------
  PA (steps)                                          -0.011 (-0.078 to 0.056)    -0.048 (-0.122 to 0.027)   -0.18 (-0.092 to 0.056)    -0.017 (-0.058 to 0.025)
  Sleep quality (MSQ score)                           0.018 (0.001 to 0.034)      0.018 (0.002 to 0.033)     0.004 (-0.017 to 0.026)    0.011 (0.002 to 0.019)
  Alcohol consumption (days)                          -0.137 (-0.272 to -0.002)   -0.111 (-0.241 to 0.019)   0.034 (-0.140 to 0.208)    -0.073 (-0.145 to -0.001)
  Smoking (yes)                                       0.157 (-0.514 to 0.828)     0.424 (-0.224 to 1.072)    0.819 (-0.376 to 2.014)    0.170 (-0.172 to 0.513)
  SB at work (frequency)                              0.021 (-0.114 to 0.157)     0.017 (-0.123 to 0.157)    0.023 (-0.154 to 0.201)    0.006 (-0.070 to 0.082)
  Sex (female)[\*](#TFN2){ref-type="table-fn"}        -0.447 (-0.900 to 0.007)    -0.341 (-0.780 to 0.098)   -0.302 (-0.731 to 0.126)   -0.421 (-0.872 to 0.029)
  Age (years)[\*](#TFN2){ref-type="table-fn"}         0.021 (-0.004 to 0.047)     0.020 (-0.004 to 0.044)    0.029 (0.003 to 0.056)     0.019 (-0.005 to 0.044)
  Body fatness (%)[\*](#TFN2){ref-type="table-fn"}    0.023 (0.003 to 0.043)      0.019 (-0.002 to 0.039)    0.027 (0.007 to 0.048)     0.020 (-0.001 to 0.040)
  SBP (mmHg)[\*](#TFN2){ref-type="table-fn"}          -0.005 (-0.028 to 0.019)    -0.005 (-0.028 to 0.017)   -0.004 (-0.028 to 0.020)   -0.005 (-0.028 to 0.018)
  DBP (mmHg)[\*](#TFN2){ref-type="table-fn"}          0.017 (-0.010 to 0.044)     0.021 (-0.005 to 0.047)    0.014 (-0.014 to 0.043)    0.020 (-0.007 to 0.046)
  Schooling (years)[\*](#TFN2){ref-type="table-fn"}   0.084 (-0.024 to 0.193)     0.091 (-0.020 to 0.202)    0.080 (-0.026 to 0.187)    0.092 (-0.019 to 0.202)
  Linear regression parameters                                                                                                           
  R                                                   0.527                       0.549                      0.473                      0.548
  r ^2^                                               0.278                       0.301                      0.224                      0.300
  r ^2^~adjusted~                                     0.191                       0.219                      0.131                      0.217

only baseline values were used; Model-A: lifestyle behaviors inserted as baseline values; Model-B: lifestyle behaviors inserted as follow-up values; Model-C: lifestyle behaviors inserted as follow-up minus baseline values; Model-D: lifestyle behaviors inserted as baseline plus follow-up values; 95%CI: 95% confidence interval; PA: physical activity; MSQ: mini-sleep questionnaire; SB: sedentary behavior; SBP: systolic blood pressure; DBP: diastolic blood pressure.

In the multivariate model considering changes over time in lifestyle behaviors (Model-C), age and body fatness were positively related to higher 12-months medicine costs. Model-C explained 13.1% of all variance in the medicine costs. In Model-D (sum of baseline and follow-up values), sleep quality had a positive relationship with medicine use ([Table 3](#t3){ref-type="table"}). On the other hand, alcohol consumption was negatively related to costs of medicine use. Model-D explained 21.7% of all variance in the medicine costs.

Discussion
==========

This study shows that lifestyle behaviors particularly worse sleep quality leads to higher costs related to medicine use. Body fatness was also found to be an important predictor - positive effect on costs. In overall, 52.5% of adults reported any medicine use during the cohort period, while 20.5% (n = 24) of these same adults reported the use of three or more medicines. These rates are similar to Brazilian (18%) and European (20%) surveys, in which population-based samplings were carried out.^[@r4],[@r5]^

Another similarity with previous studies observed in our findings is that drugs for the treatment of cardiovascular diseases were the most reported by the participants. A study carried out in New Zealand examining the trends of medicine use in adults aged ≥ 65 years from 2005 to 2013 identified that the use of drugs to prevent cardiovascular events (aspirin and statins) increased significantly.^[@r3]^ The dynamics observed for medicines to the treatment of cardiovascular diseases seems affected by aging as well (in our study, a relevant covariate in the multivariate models). Previous data have identified that consumption of aspirin and dipyridamole increased in older adults at a higher rate than observed in younger ones.^[@r3]^

The increased amount paid by older adults can be supported by the natural effects that ageing exert over organs of the human body and their functions,^[@r23]^ but also boosted by the reduced PA observed in older groups.^[@r24]^ In the analyzed sample, although the effect of age on costs with medicine use was not mediated by PA, they were related with other in crude analyzes, denoting the relevance of actions targeting the improvement of PA practice mainly in population groups composed of older adults.^[@r23],[@r24]^

In this sample, the higher cost with medicines in adults with sleep disorders can represent not only the treatment of the sleep disorders itself, but also the use of medicines to relief its symptoms and hence to maintain the daily activities, such as work.^[@r13],[@r25]^

The findings related to alcohol consumptions were surprising because usually the higher alcohol consumption is linked to higher health care costs,^[@r26],[@r27]^ and not the opposite as observed in our study. In fact, the linkage between alcohol consumption and health care costs can be direct (e.g. diseases directly linked to alcohol consumption) and indirect (e.g. traffic car accident), but it is important to take into account that some kinds of alcoholic drinks have healthy characteristics, such as anti-inflammatory properties observed in the red wine.^[@r28]^ Therefore, the explanation for our interesting finding could be due to both the type and amount of alcohol consumed. However, our study looked at only the number of days per week with alcohol consumption, and not amount and type of alcohol consumed, which characterizes a limitation in our study.

Other limitations of the study are worth mentioning. The first limitation of the study is the small sample size. The current study has statistical power of 80% to detect coefficient of correlation of 0.256 or higher, while the relationship between some behaviors and costs with medicine are around r = 0.110.^[@r16]^ Even considering the fact that the inclusion of covariates increases the power of multivariate models,^[@r29]^ the reduced sample size may have been responsible for the absence of significant relationship between PA and costs with medicine. Another limitation related to objective measures of PA is the logging of data by the participants because every day they had to note the number of steps displayed in the pedometer. Although this method is widely used,^[@r19]^ it could have led to misreporting. As above mentioned, the absence of measures of amount and kind of alcoholic drinks and sedentary behavior (by screen time on TV or computer) constitute limitations as well. Further studies could explore the impact of these.

Conclusions
===========

Worse sleep quality seems to increase the costs related to medicine use in adults, while obesity and ageing play a relevant role in this phenomenon. Moreover, alcohol consumption seems a variable with relevant economic impact, but further studies are necessary to identify clearly the direction of its relationship with medicine costs.
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